Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
  • A61K9/0007—Effervescent

Definitions

• the present invention relates to pharmaceutical formulations comprising tadalafil that shall be used in the treatment of erectile dysfunction.
• the present invention further relates to effervescent form of tadalafil.
• Tadalafil was first disclosed in the application numbered W09519978. In said document, it was disclosed that use of tadalafil is effective in the treatment of erectile dysfunction.
• Tadalafil is available in 5 mg, 10 mg and 20 mg tablet forms on the market.
• tadalafil is a molecule which is insoluble in water and slightly soluble in alcohol. It has been seen that effervescent formulations comprising the active agent tadalafil having low solubility dissolve slowly when they are put in water during use and some part of the formulation remains without dissolving and therefore a homogeneous solution cannot be obtained. This reduces absorption and bioavailability of tadalafil and therefore the patient cannot take sufficient active agent required for an efficient treatment.
• the inventors have surprisingly seen that in the case that the average particle size (d 50 value) of the active agent tadalafil in the effervescent formulations comprising tadalafil obtained is in the range of 5- 50 ⁇ , said formulations disperse quickly and easily when they are put into water, and they have a high active agent absorption and bioavailability and therefore an effective treatment is provided.
• the subject of the present invention is that the average particle size (d 50 value) of tadalafil used as the active agent in the effervescent formulation comprising tadalafil is in the range of 5- 50 ⁇ .
• the average particle size of the active agent tadalafil is preferably in the range of 10- 40 ⁇ , more preferably in the range of 12- 30 ⁇ .
• Tadalafil comprised in the formulations of the present invention is in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof in terms of chemical structure; in amorphous or crystalline form or a combination thereof in terms of polymorphic structure.
• the characteristic feature of the effervescent formulations of the present invention is that said formulations are in effervescent powder, effervescent tablet and effervescent granule form.
• the formulations are preferably in effervescent tablet form.
• the characteristic feature of the effervescent formulations of the present invention is that said formulations comprise tadalafil in the range of 0.01-10%, preferably in the range of 0.05-5%, more preferably in the range of 0.1- 3%.
• particle size of the active agent tadalafil is one of the major factors leading to failure in providing tablet weight and content uniformity in the case that said formulations do not have proper flow characteristics and thus they are compressed in tablet form.
• the inventors have found that the fact that d 10 :d 50 ratio and d 50 :d9 0 ratio are in optimum ranges is an important parameter to obtain good flow characteristics and to provide weight and content uniformity of the tablets obtained during compressing the effervescent formulations comprising the active agent tadalafil in tablet form.
• a preferred embodiment of the present invention is that d 10 :d 50 ratio of the active agent tadalafil is in the range of 2:1 to 1:15, preferably in the range of 1 :1 to 1:10 and dio:d 5 o ratio of the active agent tadalafil is in the range of 5:1 to 1 :5, preferably in the range of 2:1 to 1:4.
• d 50 used herein signifies that half of the said substance by volume has a particle size below the value stated with d 50 and the other half of the substance by volume has a particle size over the value stated with d 50.
• d 10 used herein signifies that 10% of the said substance by volume has a particle size below the value stated with d 10 and the rest of the substance has a particle size over the value stated with d 10 .
• d 90 used herein signifies that 90% of the said substance by volume has a particle size below the value stated with d 90 and the rest of the substance has a particle size over the value stated with d 90 .
• d 50 , d 10 , d 90 values can be measured by one of the known measuring devices, for instance with a device which measures particle distribution by laser diffraction (for instance, Malvern Mastersizer etc.).
• Another characteristic feature of the effervescent formulations of the present invention is that said formulations comprise at least one pharmaceutically acceptable excipient along with tadalafil.
• the pharmaceutically acceptable excipients that can be used in the effervescent formulations of the present invention can be selected from a group comprising effervescent acid, effervescent base, binder, filling agent, sweetener, flavouring agent, coloring agent and anti- foaming agent.
• the effervescent formulations comprising tadalafil according to the present invention, characterized in that the filling agent to be used is in the range of 1 -20%, preferably in the range of 2-18%, more preferably in the range of 5-15% in proportion to total formulation.
• the filling agent that can be used in the effervescent formulations of the present invention and comprising tadalafil can be selected from a group comprising D-mannitol, xylitol, microcrystalline cellulose, crospovidone, dibasic calcium phosphate, anhydrous, lactose, starch, maltose, dextrin, maltodextrin, magnesium carbonate, talc and combinations thereof.
• maltodextrin is used as the filling agent in the formulations.
• the effervescent acid that can be used in the effervescent formulations of the present invention and comprising tadalafil can be selected from a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid and tartaric acid or a combination thereof.
• the effervescent base that can be used in the effervescent formulations of the present invention and comprising tadalafil can be selected from a group comprising sodium bicarbonate, sodium citrate dihydrate, sodium hydroxide or combinations thereof.
• the binder that can be used in the effervescent formulations of the present invention and comprising tadalafil can be selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, sorbitol, methylcellulose, povidone.
• the sweetener that can be used in the effervescent formulations of the present invention and comprising tadalafil can be selected from a group comprising acesulfame potassium, aspartame, fructose, maltitol, xylitol, saccharin, sodium cyclamate, sucralose, sucrose.
• the flavouring agent that can be used in the effervescent formulations of the present invention and comprising tadalafil can be selected from menthol, methane, anethole, methyl salicylate, eucalyptol, cinnamon, 1 -methyl acetate, sage, eugenol, oxanone, lemon, orange, strawberry, blackberry or combinations thereof
• the colouring agent that can be used in the effervescent formulations of the present invention and comprising tadalafil can be selected from titanium dioxide, chlorophyll, yellow iron oxide, other synthetic iron oxides, beta-carotene or combinations thereof.
• the anti-foaming agent that can be used in the effervescent formulations of the present invention and comprising tadalafil can be selected from polydimethylsiloxane, simethicone, other silicones, stearates, alcohols, glycols or combinations thereof.
• effervescent formulations of the present invention comprising tadalafil, characterized in that the amount of the active agent is in the range of 0.01-10%, effervescent acid in the range of 1-80%, effervescent base in the range of 1-70%, binder in the range of 1-30%, sweetener in the range of 1-30%, flavouring agent in the range of 0.1-10%, colouring agent in the range of 0.01-10%, anti-foaming agent in the range of 0.001-2% in proportion to total formulation.
• the method for preparation of the effervescent formulations of the present invention and comprising tadalafil can be composed of the following steps:
• the effervescent acid, the effervescent base, the binder, the sweetener and the filling agent are mixed and granulated with the granulation solution comprising tadalafil.
• the granulation solution used herein can comprise a solvent in addition to tadalafil.
• the granules obtained in the I st step are dried and sieved.
• flavouring agent the colouring agent and the anti foaming agent are added into the granules obtained in the II nd step and final mixture is obtained.
• the final mixture obtained is compressed in tablet form or filled into the sachets.
• the pharmaceutical formulation according to the present invention can be used in prevention and treatment of erectile dysfunction.
• Example 1 Formulation and process for preparation of tadalafil effervescent tablet
• effervescent acid, the effervescent base, the binder, the sweetener and maltodextrin are mixed and granulated with the granulation solution comprising tadalafil.
• the granules obtained in the II nd step are dried and sieved.
• the flavouring agent, the colouring agent and the anti-foaming agent are added into the granules in the II nd step and the final mixture is obtained.
• the final mixture obtained is compressed in tablet form or filled into sachets.

Landscapes

• Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=48083584

Family Applications (1)

Country Status (1)

Cited By (4)

Citations (7)

• 2013
  • 2013-01-18 WO PCT/TR2013/000036 patent/WO2013109223A1/fr not_active Ceased

Patent Citations (7)

Similar Documents

Legal Events